Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EBT: 2023-2025

Historic EBT for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to -$43.7 million.

  • CG Oncology's EBT fell 114.22% to -$43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.4 million, marking a year-over-year decrease of 107.99%. This contributed to the annual value of -$88.0 million for FY2024, which is 81.36% down from last year.
  • Latest data reveals that CG Oncology reported EBT of -$43.7 million as of Q3 2025, which was down 5.52% from -$41.4 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's EBT registered a high of -$8.7 million during Q1 2023, and its lowest value of -$43.7 million during Q3 2025.
  • Its 3-year average for EBT is -$23.3 million, with a median of -$18.9 million in 2024.
  • Data for CG Oncology's EBT shows a maximum YoY tumbled of 119.05% (in 2025) over the last 5 years.
  • Over the past 3 years, CG Oncology's EBT (Quarterly) stood at -$16.6 million in 2023, then slumped by 92.16% to -$31.8 million in 2024, then tumbled by 114.22% to -$43.7 million in 2025.
  • Its last three reported values are -$43.7 million in Q3 2025, -$41.4 million for Q2 2025, and -$34.5 million during Q1 2025.